Review of Pharmacologic Considerations in the Use of Azole Antifungals in Lung Transplant Recipients
Keyword(s):
Mold-active azole antifungals are commonly prescribed for the prevention of invasive fungal infections in lung transplant recipients. Each agent exhibits a unique pharmacologic profile, an understanding of which is crucial for therapy selection and optimization. This article reviews pharmacologic considerations for three frequently-used azole antifungals in lung transplant recipients: voriconazole, posaconazole, and isavuconazole. Focus is drawn to analysis of drug-interactions, adverse drug reactions, pharmacokinetic considerations, and the role of therapeutic drug monitoring with special emphasis on data from the post-lung transplant population.
2013 ◽
Vol 32
(4)
◽
pp. S189
◽
2020 ◽
2019 ◽
Vol 6
(Supplement_2)
◽
pp. S636-S636
2017 ◽
Vol 36
(4)
◽
pp. S240
2011 ◽
Vol 30
(4)
◽
pp. S42-S43
2017 ◽
Vol 73
(3)
◽
pp. 748-756
◽
2012 ◽
Vol 56
(5)
◽
pp. 2371-2377
◽